Press Release: Sanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema

Press Release: Sanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema

Sanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi's commitment to developing treatments for rare diseases Efdoralprin alfa, an investigational restorative recombinant therapy, recently met all primary and key secondary endpoints in phase 2 head-to-head study versus a plasma-derived standard of care Paris, December 17, 2025. The Europe…